Abstract Number: 0105 • ACR Convergence 2026
Gene expression signatures as predictors of response to methotrexate in pediatric non-infectious uveitis (NIU).
Background/Purpose: Methotrexate (MTX) is the recommended first-line treatment for children with non-infectious uveitis (NIU), with treatment failure rates as high as 50%. Because therapeutic response…Abstract Number: 1329 • ACR Convergence 2026
Single Nucleus RNA Sequencing of Methylprednisolone Effects Reveals Biomarkers in PsA Synovial Lining Fibroblasts
Background/Purpose: Intra-articular glucocorticoid injections are used to treat RA and PsA. Much is known about glucocorticoid effects but a more detailed understanding of their effects…Abstract Number: 2048 • ACR Convergence 2026
Unique Type 1 and Type 2 Interferon (IFN) Response Gene Score Longitudinal Changes in Refractory Juvenile Dermatomyositis (JDM) Patients Receiving Baricitinib by Single-Cell RNA Sequencing
Background/Purpose: JDM is a rare heterogenous systemic autoimmune condition. Though pathogenesis is incompletely understood, dysregulated type I/II IFN signaling is well documented. Patients with refractory…Abstract Number: 0128 • ACR Convergence 2026
Cellular and Transcriptional Differences Across Early Sjögren’s Disease Subphenotypes
Background/Purpose: Sjögren's Disease (SjD) lacks an established definition of early disease. To study early disease mechanisms, the Sjögren's Team for Accelerating Medicines Partnership (STAMP) defined…Abstract Number: 1525 • ACR Convergence 2026
Transcriptomic Profiling Reveals Biologically Distinct Subgroups in Newly Diagnosed Children and Adolescents with Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a heterogeneous disease both clinically and genetically. Using treatment-naïve gene expression profiles, we aimed to identify homogenous transcriptomic…Abstract Number: 2057 • ACR Convergence 2026
Distinct Clonal Expansions of GZMB+ CD8+ Terminally Differentiated Effector Memory T (TEMRA) Cells Characterize Blood of Inclusion Body Myositis Patients
Background/Purpose: Inclusion body myositis (IBM) is an inflammatory myopathy of unclear etiology. Previous studies using flow cytometry and spectratyping have identified clonal populations of cytotoxic…Abstract Number: 0134 • ACR Convergence 2026
Molecular Characterization of Heterogeneity in Sjögren’s Disease and Non-Sjögren’s Sicca Syndrome
Background/Purpose: Sjögren's disease (SjD) is a clinically and molecularly heterogeneous systemic autoimmune disease. Anti-Ro negative (anti-Ro-) SjD patients are underrepresented in research studies and often…Abstract Number: 1573 • ACR Convergence 2026
Automated Synovial Mast Cell Quantification Reveals Associations with Pain, Obesity and Interferon Related Inflammation in Osteoarthritis
Background/Purpose: Mast cells have been implicated in the pathogenesis of osteoarthritis (OA) [1]. We hypothesized that mast cell infiltration in synovial tissue may contribute to…Abstract Number: 2058 • ACR Convergence 2026
Peripheral Blood Transcriptomics Reveals a Distinct Immune Network Architecture in Anti-MDA5 Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is a severe subtype of idiopathic inflammatory myopathy (IIM) characterized by rapidly progressive interstitial lung disease and…Abstract Number: 0264 • ACR Convergence 2026
Distinct Multi-omic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) typically follows a relapsing-remitting course. Mycophenolate mofetil (MMF) is a cornerstone therapy for SLE, yet long‑term use is limited by…Abstract Number: 1646 • ACR Convergence 2026
Blood transcriptome and serum protein biomarkers associated with tophaceous gout
Background/Purpose: In gout, the presence of tophi has important clinical implications, including associations with increased functional impairment and mortality and a lower likelihood of achieving…Abstract Number: 2066 • ACR Convergence 2026
A Genome-Scale, In Vivo Transcription Factor Screen Identifies a Previously Unrecognized Factor That Enhances CAR-T Persistence and Tumor Control Under High-Dose Rechallenge
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapy holds great promise for cancer and a growing range of immune-mediated diseases, but responses are not always durable,…Abstract Number: 0443 • ACR Convergence 2026
Characterizing the mode of action of the oral TNFR1 signal inhibitor, balinatunfib, in rheumatoid arthritis
Background/Purpose: Balinatunfib (SAR441566) is a first-in-class oral small molecule that selectively inhibits pro-inflammatory TNFR1-mediated signaling while preserving TNFR2-mediated signaling important for immune homeostasis. Here, we…Abstract Number: 1962 • ACR Convergence 2026
An Integrated Multi-Agent System for Accelerating Rheumatology Research
Background/Purpose: Rheumatology research requires continuous literature surveillance, analysis of multidimensional data across fragmented tools, and integration of datasets from different platforms, which are generated faster…Abstract Number: 2084 • ACR Convergence 2026
Immunometabolic changes associated with sustained remission in patients with SLE and JDM treated with anti-CD19 CAR-T cells
Background/Purpose: Anti-CD19-CAR T-cell therapy is an innovative strategy to induce profound B cell depletion in patients with refractory autoimmune diseases, allowing to reach a sustained…
